Skip to main content
SpringerLink
Log in

GPCRs as Targets for Plant-Derived Drugs

  • Chapter
  • First Online:
Lessons on Caffeine, Cannabis & Co

Part of the book series: Learning Materials in Biosciences ((LMB))

  • 1799 Accesses

Abstract

The family of GPCRs represents the most important class of pharmaceutical drug targets. In this chapter, we describe such receptors and pathways that are targets for well-known plant-derived drugs and toxins. These include adrenergic receptors, the muscarinic acetylcholine receptor (MAchR), adenosine receptors, cannabinoid receptors, dopamine- and serotonin (5HT) receptors/transporters and opiate receptors. They are targets for compounds such as cannabis, muscarine and atropine, caffeine, cocaine, morphine and hallucinogenic drugs, among others.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alagha K, Palot A, Sofalvi T, Pahus L, Gouitaa M, Tummino C, Martinez S, Charpin D, Bourdin A, Chanez P (2014) Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis 5:85–98

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barnes PJ (2013) Theophylline. Am J Respir Crit Care Med 188:901–906

    Article  CAS  PubMed  Google Scholar 

  • Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182–217

    Article  CAS  PubMed  Google Scholar 

  • Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6:237–249

    Article  CAS  PubMed  Google Scholar 

  • Borea PA, Varani K, Vincenzi F, Baraldi PG, Tabrizi MA, Merighi S, Gessi S (2015) The A3 adenosine receptor: history and perspectives. Pharmacol Rev 67:74–102

    Article  PubMed  Google Scholar 

  • Boyd KN, Mailman RB (2012) Dopamine receptor signaling and current and future antipsychotic drugs. Handb Exp Pharmacol 212:53–86

    Google Scholar 

  • Brown SP, Safo PK, Regehr WG (2004) Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels. J Neurosci 24:5623–5631

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Catterall WA (2015) Regulation of cardiac calcium channels in the fight-or-flight response. Curr Mol Pharmacol 8:12–21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cross SA (1994) Pathophysiology of pain. Mayo Clin Proc 69:375–383

    Article  CAS  PubMed  Google Scholar 

  • Dalton GD, Bass CE, Van Horn CG, Howlett AC (2009) Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets 8:422–431

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davis RL, Cherry J, Dauwalder B, Han PL, Skoulakis E (1995) The cyclic AMP system and Drosophila learning. Mol Cell Biochem 149–150:271–278

    Article  PubMed  Google Scholar 

  • de Lera Ruiz M, Lim YH, Zheng J (2014) Adenosine A2A receptor as a drug discovery target. J Med Chem 57:3623–3650

    Article  PubMed  Google Scholar 

  • De Petrocellis L, Nabissi M, Santoni G, Ligresti A (2017) Actions and regulation of ionotropic cannabinoid receptors. Adv Pharmacol 80:249–289

    Article  PubMed  Google Scholar 

  • Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, Bolanowski MA, Bennett CD, Rands E, Diehl RE, Mumford RA, Slater EE, Sigal IS, Caron MG, Lefkowitz RJ, Strader CD (1986) Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 321:75–79

    Article  CAS  PubMed  Google Scholar 

  • Eiden LE, Weihe E (2011) VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann N Y Acad Sci 1216:86–98

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fergus IV, Connell KL, Ferdinand KC (2015) A comparison of vasodilating and non-VASODILATING beta-blockers and their effects on cardiometabolic risk. Curr Cardiol Rep 17:38

    Article  PubMed  Google Scholar 

  • Ferre S (2010) Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine. J Alzheimer’s Dis: JAD 20(Suppl 1):S35–S49

    Article  CAS  Google Scholar 

  • Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, Park G, Adney SK, Hatcher C, Eltit JM, Ruta JD, Albizu L, Li Z, Umali A, Shim J, Fabiato A, MacKerell AD Jr, Brezina V, Sealfon SC, Filizola M, Gonzalez-Maeso J, Logothetis DE (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147:1011–1023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hoffer A (1967) A program for the treatment of alcoholism: LSD, malvaria and nicotinic acid. In: Abramson HA (ed) The use of LSD in psychotherapy and alcoholism. Bobbs-Merrill, Indianapolis, pp 343–406

    Google Scholar 

  • Hokfelt T (2010) Looking at neurotransmitters in the microscope. Prog Neurobiol 90:101–118

    Article  PubMed  Google Scholar 

  • Huang ZL, Urade Y, Hayaishi O (2011) The role of adenosine in the regulation of sleep. Curr Top Med Chem 11:1047–1057

    Article  CAS  PubMed  Google Scholar 

  • Johnson KA, Lovinger DM (2016) Presynaptic G protein-coupled receptors: gatekeepers of addiction? Front Cell Neurosci 10:264

    Article  PubMed  PubMed Central  Google Scholar 

  • Kivell BM, Ewald AW, Prisinzano TE (2014) Salvinorin A analogs and other kappa-opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol 69:481–511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, Echigo N, Kemmotsu O, Hattori Y, Gando S (2003) The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release? Anesth Analg 97:1239–1245

    Article  CAS  PubMed  Google Scholar 

  • Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hubner H, Pardon E, Valant C, Sexton PM, Christopoulos A, Felder CC, Gmeiner P, Steyaert J, Weis WI, Garcia KC, Wess J, Kobilka BK (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504:101–106

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, Wess J (2014) Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov 13:549–560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Landolt HP (2008) Sleep homeostasis: a role for adenosine in humans? Biochem Pharmacol 75:2070–2079

    Article  CAS  PubMed  Google Scholar 

  • Lemieux G, Davignon A, Genest J (1956) Depressive states during Rauwolfia therapy for arterial hypertension; a report of 30 cases. Can Med Assoc J 74:522–526

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lewin L (1964) Phantastica, narcotic, and stimulating drugs. their use and abuse. Routledge, London

    Google Scholar 

  • Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, Khan IA, Feller DR (2007) Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes. J Pharmacol Exp Ther 322:214–221

    Article  CAS  PubMed  Google Scholar 

  • Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168:299–325

    Google Scholar 

  • Melancon BJ, Tarr JC, Panarese JD, Wood MR, Lindsley CW (2013) Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer’s disease. Drug Discov Today 18:1185–1199

    Article  CAS  PubMed  Google Scholar 

  • Merighi A, Salio C, Ferrini F, Lossi L (2011) Neuromodulatory function of neuropeptides in the normal CNS. J Chem Neuroanat 42:276–287

    Article  CAS  PubMed  Google Scholar 

  • Mustard JA (2014) The buzz on caffeine in invertebrates: effects on behavior and molecular mechanisms. Cell Mol Life Sci: CMLS 71:1375–1382

    Article  CAS  PubMed  Google Scholar 

  • Nehlig A, Armspach JP, Namer IJ (2010) SPECT assessment of brain activation induced by caffeine: no effect on areas involved in dependence. Dialogues Clin Neurosci 12:255–263

    PubMed  PubMed Central  Google Scholar 

  • Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181

    Article  CAS  PubMed  Google Scholar 

  • Nickalls RW, Nickalls EA (1988) The first use of physostigmine in the treatment of atropine poisoning. A translation of Kleinwachter’s paper entitled 'Observations on the effect of Calabar bean extract as an antidote to atropine poisoning. Anaesthesia 43:776–779

    Article  CAS  PubMed  Google Scholar 

  • Nyiri G, Cserep C, Szabadits E, Mackie K, Freund TF (2005) CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 136:811–822

    Article  CAS  PubMed  Google Scholar 

  • Ogrodowczyk M, Dettlaff K, Jelinska A (2016) Beta-blockers: current state of knowledge and perspectives. Mini Rev Med Chem 16:40–54

    Article  CAS  PubMed  Google Scholar 

  • Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M (2012) Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 18:119–132

    Article  CAS  PubMed  Google Scholar 

  • Osmond H, Smythies J (1952) Schizophrenia: a new approach. J Ment Sci 98:309–315

    Article  CAS  PubMed  Google Scholar 

  • Pasternak GW, Pan YX (2013) Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 65:1257–1317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Paul K, Ruck CA, Bigwood J, Staples D, Ott J, Wasson RG (1979) Entheogens. J Psychedelic Drugs 11:145–146

    Article  Google Scholar 

  • Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180

    CAS  PubMed  Google Scholar 

  • Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215

    Article  CAS  PubMed  Google Scholar 

  • Pessah IN, Stambuk RA, Casida JE (1987) Ca2+−activated ryanodine binding: mechanisms of sensitivity and intensity modulation by Mg2+, caffeine, and adenine nucleotides. Mol Pharmacol 31:232–238

    CAS  PubMed  Google Scholar 

  • Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK (2007) Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450:383–387

    Article  CAS  PubMed  Google Scholar 

  • Rivera-Oliver M, Diaz-Rios M (2014) Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. Life Sci 101:1–9

    Article  PubMed  PubMed Central  Google Scholar 

  • Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA (2003) In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 307:138–145

    Article  CAS  PubMed  Google Scholar 

  • Seeman P (2014) Clozapine, a fast-off-D2 antipsychotic. ACS Chem Neurosci 5:24–29

    Article  CAS  PubMed  Google Scholar 

  • Shamon SD, Perez MI (2009) Blood pressure lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev:CD007655

    Google Scholar 

  • Shannon M, Neuman MI (2000) Yohimbine. Pediatr Emerg Care 16:49–50

    Article  CAS  PubMed  Google Scholar 

  • Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:1033–1039

    Article  PubMed  Google Scholar 

  • Simonson B, Morani AS, Ewald AW, Walker L, Kumar N, Simpson D, Miller JH, Prisinzano TE, Kivell BM (2015) Pharmacology and anti-addiction effects of the novel kappa opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A. Br J Pharmacol 172:515–531

    Article  CAS  PubMed  Google Scholar 

  • Stacy M, Silver D (2008) Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. Parkinsonism Relat Disord 14:85–92

    Article  PubMed  Google Scholar 

  • Thiele A (2013) Muscarinic signaling in the brain. Annu Rev Neurosci 36:271–294

    Article  CAS  PubMed  Google Scholar 

  • Tso PH, Wong YH (2003) Molecular basis of opioid dependence: role of signal regulation by G-proteins. Clin Exp Pharmacol Physiol 30:307–316

    Article  CAS  PubMed  Google Scholar 

  • Ulugol A (2014) The endocannabinoid system as a potential therapeutic target for pain modulation. Balkan Med J 31:115–120

    Article  PubMed  PubMed Central  Google Scholar 

  • Vansal SS, Feller DR (1999) Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol 58:807–810

    Article  CAS  PubMed  Google Scholar 

  • Vaughan RA, Foster JD (2013) Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci 34:489–496

    Article  CAS  PubMed  Google Scholar 

  • Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588–592

    Article  CAS  PubMed  Google Scholar 

  • Yeh B (2012) The controlled substances act: regulatory requirements. Congressional Res Serv:1–17

    Google Scholar 

  • Zajdel P, Bednarski M, Sapa J, Nowak G (2015) Ergotamine and nicergoline - facts and myths. Pharmacol Rep: PR 67:360–363

    Article  CAS  PubMed  Google Scholar 

  • Zhang N, Lian Z, Peng X, Li Z, Zhu H (2017) Applications of higenamine in pharmacology and medicine. J Ethnopharmacol 196:242–252

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department Biology II, LMU Munich, Planegg-Martinsried, Germany

    Angelika Böttger

  2. IZMB-Plant Cell Biology, University of Bonn, Bonn, Germany

    Ute Vothknecht

  3. Department Biology I, LMU Munich, Planegg-Martinsried, Germany

    Cordelia Bolle

  4. Inst. Molecular Toxicology/Pharmacology, Helmholtz Zentrum Münich, Neuherberg, Germany

    Alexander Wolf

Authors
  1. Angelika Böttger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ute Vothknecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cordelia Bolle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexander Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelika Böttger .

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Böttger, A., Vothknecht, U., Bolle, C., Wolf, A. (2018). GPCRs as Targets for Plant-Derived Drugs. In: Lessons on Caffeine, Cannabis & Co. Learning Materials in Biosciences. Springer, Cham. https://doi.org/10.1007/978-3-319-99546-5_5

Download citation

Publish with us

Policies and ethics

Search

Navigation